Energy recovery device manufacturer Energy Recovery (NASDAQ:ERII) reported Q3 CY2025 results topping the market’s revenue expectations, but sales fell by 17.1% year on year to $32 million. Its non-GAAP profit of $0.12 per share was 24.1% above analysts’ consensus estimates.
Ride sharing service Lyft (NASDAQ: LYFT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 10.7% year on year to $1.69 billion. Its GAAP profit of $0.11 per share was 53.6% above analysts’ consensus estimates.
Refrigerant services company Hudson Technologies (NASDAQ:HDSN) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 19.5% year on year to $74.01 million. Its GAAP profit of $0.27 per share was 40.3% above analysts’ consensus estimates.
Healthcare distributor and services company McKesson (NYSE:MCK) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 10.1% year on year to $103.2 billion. Its non-GAAP profit of $9.86 per share was 8.9% above analysts’ consensus estimates.
Business payments company Corpay (NYSE:CPAY) announced better-than-expected revenue in Q3 CY2025, with sales up 13.9% year on year to $1.17 billion. The company’s full-year revenue guidance of $4.52 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $5.70 per share was 1% above analysts’ consensus estimates.
Customer experience software company CSG Systems (NASDAQ:CSGS) met Wall Streets revenue expectations in Q3 CY2025, with sales up 2.9% year on year to $303.6 million. Its non-GAAP profit of $1.31 per share was 17.3% above analysts’ consensus estimates.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 6.7% year on year to $1.13 billion. The company expects the full year’s revenue to be around $4.23 billion, close to analysts’ estimates. Its non-GAAP profit of $8.13 per share was 39% above analysts’ consensus estimates.
Buy-now-pay-later service Sezzle (NASDAQCM:SEZL) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 67% year on year to $116.8 million. Its GAAP profit of $0.75 per share was 15.4% above analysts’ consensus estimates.
As November 2025 unfolds, the financial markets are grappling with a complex and often contradictory narrative emanating from the Federal Reserve. The central bank has recently embarked on a path of monetary easing, delivering two consecutive 25-basis-point rate cuts in September and October, bringing the federal funds rate to a
The October 2025 ADP National Employment Report has injected a fresh wave of complexity into the Federal Reserve's delicate balancing act, revealing a private sector that added 42,000 jobs – a figure significantly surpassing economists' projections. This unexpected surge in employment, the first monthly gain since July, arrives amidst a
IREN shares are trading higher Wednesday after the company recently signed a $9.7 billion AI cloud services agreement with Microsoft to deploy NVIDIA GB300 GPUs across its 750 MW Texas campus.
The global stock market in November 2025 presents a fascinating dichotomy, a landscape where robust year-to-date gains clash with mounting concerns over stretched valuations and a palpable shift in investor sentiment. While major indices have enjoyed a remarkably strong year, propelled by an insatiable appetite for artificial intelligence (AI) innovation
The financial markets, still reeling from a tumultuous period marked by significant downturns, are now grappling with an uneasy attempt at consolidation. As of November 5, 2025, investors are witnessing a landscape fundamentally altered by a series of sharp slides, most notably the tariff-induced crash of April 2025 and a
SPXL and TQQQ both offer daily 3x leveraged exposure, but SPXL focuses on the S&P 500 while TQQQ targets the tech-heavy Nasdaq-100, leading to deeper drawdowns for TQQQ.
Shares of content discovery platform Taboola (NASDAQ:TBLA) jumped 5.5% in the morning session after the company reported strong third-quarter financial results that surpassed expectations and provided an optimistic forecast for the upcoming quarter. Revenue for the quarter reached $496.8 million, growing 14.7% year on year and comfortably beating analysts' forecasts. The company also swung to a profit, with GAAP earnings of $0.02 per share, which was ahead of Wall Street's expectations and a notable improvement from the loss of $0.02 per share recorded in the prior year's quarter. Looking ahead, Taboola's revenue guidance for the fourth quarter was also surprisingly strong, coming in 3.3% above consensus estimates. Overall, it was a solid quarter for the company, highlighted by broad-based beats and a strong outlook.
Shares of self defense company AXON (NASDAQ:AXON)
fell 18.5% in the morning session after the company reported third-quarter results that missed profit expectations and provided weak EBITDA guidance for the upcoming quarter. While revenue for the quarter grew 30.6% year-on-year to $710.6 million, beating Wall Street's estimates, investors focused on the negatives. The company's adjusted earnings per share of $1.17 came in 24.1% below the consensus estimate of $1.54. Furthermore, Axon's EBITDA guidance for the fourth quarter was below analyst expectations. The company also saw its operating margin contract, falling to -0.3% from 4.4% in the same quarter last year, indicating rising expenses were outpacing revenue growth. Despite the earnings miss, the company's revenue guidance for the next quarter was slightly ahead of forecasts.
The financial markets as of November 5, 2025, present a compelling dichotomy with the technology and pharmaceutical sectors charting distinct yet largely positive courses. While technology continues its robust ascent, fueled by the insatiable demand for Artificial Intelligence (AI) and its underlying infrastructure, the pharmaceutical sector demonstrates a resilient recovery,
The financial markets are currently navigating a complex and often contradictory economic landscape, heavily influenced by a suite of critical indicators such as jobs data and the Purchasing Managers' Index (PMI). From late 2024 through November 2025, these barometers of economic health have signaled a period of deliberate rebalancing, characterized
The global financial markets are currently gripped by a palpable sense of unease, as significant stock swings and heightened volatility define the investment landscape of late 2025. This turbulent period is primarily driven by a complex interplay of geopolitical tensions, evolving interest rate expectations, and lingering concerns over inflated valuations
The U.S. stock market has entered November 2025 with a complex narrative, characterized by both robust bullish momentum and burgeoning concerns over valuations, particularly within the high-flying technology sector. Major global stock market indices – the Dow Jones Industrial Average (DJIA), Nasdaq Composite, and S&P 500 – have exhibited a
As November 2025 unfolds, the financial markets are characterized by a palpable sense of cautious optimism, a sentiment largely underpinned by the continued prevalence and success of "dip-buying" strategies. Despite a backdrop of evolving economic conditions and geopolitical nuances, investors—both institutional and retail—are demonstrating a remarkable resilience, viewing
In the intricate tapestry of global financial markets, few metrics hold as much sway and immediate relevance as market capitalization. Representing the total dollar value of a company's outstanding shares, market cap is a dynamic barometer of investor sentiment, corporate health, and future potential. Significant shifts in this valuation, often
The financial markets are once again in the throes of earnings season, a period that consistently proves to be a crucible for individual stock valuations and a significant driver of broader market sentiment. Recent corporate earnings reports, spanning from late 2024 through the third quarter of 2025, have painted a
